Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

47 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Desloratadine has no clinically relevant electrocardiographic or pharmacodynamic interactions with ketoconazole.
Banfield C, Herron J, Keung A, Padhi D, Affrime M. Banfield C, et al. Among authors: keung a. Clin Pharmacokinet. 2002;41 Suppl 1:37-44. doi: 10.2165/00003088-200241001-00006. Clin Pharmacokinet. 2002. PMID: 12169045 Clinical Trial.
Renal insufficiency has no effect on the pharmacokinetics of vicriviroc in a ritonavir-containing regimen.
Kasserra C, Sansone-Parsons A, Keung A, Tetteh E, Assaf M, O'Mara E, Marbury T. Kasserra C, et al. Among authors: keung a. Clin Pharmacokinet. 2010 Jun;49(6):397-406. doi: 10.2165/11319470-000000000-00000. Clin Pharmacokinet. 2010. PMID: 20481650 Clinical Trial.
Pharmacokinetics of dolasetron with coadministration of cimetidine or rifampin in healthy subjects.
Dimmitt DC, Cramer MB, Keung A, Arumugham T, Weir SJ. Dimmitt DC, et al. Among authors: keung a. Cancer Chemother Pharmacol. 1999;43(2):126-32. doi: 10.1007/s002800050872. Cancer Chemother Pharmacol. 1999. PMID: 9923817 Clinical Trial.
Enzyme induction observed in healthy volunteers after repeated administration of rifapentine and its lack of effect on steady-state rifapentine pharmacokinetics: part I.
Keung A, Reith K, Eller MG, McKenzie KA, Cheng L, Weir SJ. Keung A, et al. Int J Tuberc Lung Dis. 1999 May;3(5):426-36. Int J Tuberc Lung Dis. 1999. PMID: 10331733 Clinical Trial.
Single and multiple dose pharmacokinetics of rifapentine in man: part II.
Keung A, Eller MG, McKenzie KA, Weir SJ. Keung A, et al. Int J Tuberc Lung Dis. 1999 May;3(5):437-44. Int J Tuberc Lung Dis. 1999. PMID: 10331734 Clinical Trial.
Single-dose pharmacokinetics of rifapentine in women.
Keung AC, Eller MG, Weir SJ. Keung AC, et al. J Pharmacokinet Biopharm. 1998 Feb;26(1):75-85. doi: 10.1023/a:1023276808298. J Pharmacokinet Biopharm. 1998. PMID: 9773393
Pharmacokinetic/pharmacodynamic modeling of the antiretroviral activity of the CCR5 antagonist Vicriviroc in treatment experienced HIV-infected subjects (ACTG protocol 5211).
Crawford KW, Li C, Keung A, Su Z, Hughes MD, Greaves W, Kuritzkes D, Gulick R, Flexner C; ACTG A5211 Study Team. Crawford KW, et al. Among authors: keung a. J Acquir Immune Defic Syndr. 2010 Apr;53(5):598-605. doi: 10.1097/QAI.0b013e3181c9caac. J Acquir Immune Defic Syndr. 2010. PMID: 20071999 Free PMC article. Clinical Trial.
Pharmacokinetics of rifapentine in patients with varying degrees of hepatic dysfunction.
Keung AC, Eller MG, Weir SJ. Keung AC, et al. J Clin Pharmacol. 1998 Jun;38(6):517-24. doi: 10.1002/j.1552-4604.1998.tb05789.x. J Clin Pharmacol. 1998. PMID: 9650541 Clinical Trial.
Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults.
Schürmann D, Fätkenheuer G, Reynes J, Michelet C, Raffi F, van Lier J, Caceres M, Keung A, Sansone-Parsons A, Dunkle LM, Hoffmann C. Schürmann D, et al. Among authors: keung a. AIDS. 2007 Jun 19;21(10):1293-9. doi: 10.1097/QAD.0b013e3280f00f9f. AIDS. 2007. PMID: 17545705 Clinical Trial.
Short-term administration of the CCR5 antagonist vicriviroc to patients with HIV and HCV coinfection is safe and tolerable.
Fätkenheuer G, Hoffmann C, Slim J, Rouzier R, Keung A, Li J, Treitel M, Sansone-Parsons A, Kasserra C, O'Mara E, Schürmann D. Fätkenheuer G, et al. Among authors: keung a. J Acquir Immune Defic Syndr. 2010 Jan;53(1):78-85. doi: 10.1097/QAI.0b013e3181bb28dc. J Acquir Immune Defic Syndr. 2010. PMID: 19838130 Clinical Trial.
47 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback